Table 2 Frequency breakdown of category of CMD participants by COVID-19 status
Category | Positive | Negative | Total | Relative risk (95% CI) | ||
|---|---|---|---|---|---|---|
N | % | N | % | |||
Angiotensin converting enzyme inhibitor | 6 | 20.69 | 44 | 17.53 | 50 | 1.18 (0.551, 2.527) |
Anti-coagulant | 2 | 6.9 | 5 | 1.99 | 7 | 3.46 (0.703, 17.048) |
Anti-platelet | 4 | 13.79 | 27 | 10.76 | 31 | 1.28 (0.483, 3.407) |
Angiotensin receptor blocker | 3 | 10.34 | 35 | 13.94 | 38 | 0.74 (0.243, 2.262) |
Beta-blocker | 5 | 17.24 | 52 | 20.72 | 57 | 0.83 (0.362, 1.915) |
Calcium channel blockers | 3 | 10.34 | 35 | 13.94 | 38 | 0.74 (0.243, 2.262) |
Non-statin hyperlipidemia treatment | 5 | 17.24 | 33 | 13.15 | 38 | 1.31 (0.556, 3.094) |
Diuretic | 2 | 6.9 | 43 | 17.13 | 45 | 0.4 (0.103, 1.576) |
Insulin | 0 | 0 | 13 | 5.18 | 13 | 0.33 (0.02, 5.465) |
Insulin sensitizer | 1 | 3.45 | 56 | 22.31 | 57 | 0.15 (0.022, 1.075) |
Statin | 7 | 24.14 | 66 | 26.29 | 73 | 0.92 (0.466, 1.808) |
Sulfonylurea | 0 | 0 | 15 | 5.98 | 15 | 0.29 (0.018, 4.703) |
Thyroid medication | 8 | 27.59 | 65 | 25.9 | 73 | 1.07 (0.57, 1.992) |
No treatment | 6 | 20.69 | 0 | 0 | 6 | 103.86 (5.952, 1812.352)a |